Meeting
2022 ASCO Annual Meeting
Survival of elderly patients with HER2+/HR- metastatic breast cancer in clinical practice: SEER-Medicare data 2012-2016.
Authors
Zhonghui Ou
MCPHS University, Boston, MA
Zhonghui Ou , Laura Spring , Anju Nohria , John D. Seeger , Irene Murimi-Worstell
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer—Metastatic
Track
Breast Cancer
Sub Track
HER2-Positive
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 1039)
DOI
10.1200/JCO.2022.40.16_suppl.1039
Abstract #
1039
Poster Bd #
417
Abstract Disclosures
Similar Posters
Poster
2020 ASCO Virtual Scientific Program
SOPHIA analysis by chemotherapy (Ctx) choice: A phase III (P3) study of margetuximab (M) + Ctx versus trastuzumab (T) + Ctx in patients (pts) with pretreated HER2+ metastatic (met) breast cancer (MBC).
First Author: Santiago Escrivá
Poster
2014 ASCO Annual Meeting
A phase II study of eribulin mesylate in combination with trastuzumab and pertuzumab in patients (pts) with metastatic, human epidermal growth factor receptor 2-positive breast cancer.
First Author: Rachel A. Freedman
Poster
2023 ASCO Breakthrough
Retrospective observational study of outcomes in HER2-positive metastatic breast cancer patients treated with trastuzumab emtansine in single center.
First Author: WanChen Hsieh
First Author: Nicholas Patrick McAndrew